ArticleFuture medicinal chemistry2025
Anti-adhesive glycoconjugates against
Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthesis of mono- and di-(Frontiers in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo explore novel anti-virulence strategies against Candida albicans by evaluating the structure-activity relationship (SAR) of aromatic glycoconjugates that inhibit fungal adhesion to buccal epithelial cells (BECs), focusing on the effect of the substituents on the aromatic ring. MATERIALS &
methodsA series of aromatic glycoconjugates containing divalent β-D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide motif, important for anti-adhesion activity, were synthesized and assessed as inhibitors of C. albicans adhesion to BECs. The impact of various aromatic substituents on anti-adhesion activity was systematically analyzed. Conformational studies were conducted to investigate the spatial orientation of galactose moieties in active compounds.
resultsGlycoconjugates with less sterically hindered and more lipophilic aromatic substituents, such as cyclopropyl groups, demonstrated enhanced inhibition of C. albicans adhesion. Conformational analysis revealed that the most active compounds consistently adopted a "closed" orientation of the galactose moieties, regardless of the nature of the aromatic substituent.
conclusionsAromatic glycoconjugates with specific structural features, particularly lipophilic and compact substituents, show promise as anti-adhesion agents against C. albicans. These findings support the potential of anti-virulence strategies targeting fungal adhesion as alternatives to traditional fungicidal therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.